Nissan Chemical Industries Limited

Other

Reprocell, Inc.

Katsuaki Miyaji

Norihisa Ishiwata

Kazufumi Yanagihara

Shunsuke Iwamoto

Fumie Sato

Kazutaka Arai

Takanori Nakamura

Yutaka Hirokawa

Taito Nishino

Shingo Owada

Yukihiro Shigeta

Hirofumi Ota

Satoshi Nakano

Shingo Umezawa

Keizo Tanikawa

Masato Horikawa

Hitomi Suzuki

Yasuyuki Asai

Masao Yamamoto

Koichi Maeda

Yoshio Ohara

Takehiro Amano

Koichiro Saruhashi

Yasuhiro Takahashi

Takumi Mikashima

Makiko Yui

Yo Kishikawa

Shunuske Iwamoto

Shingo Oowada

Hisao Kamiya

Atsushi Miyamura

Nobuhiro Suzuki

An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy useful for treatment of various hematopoietic disorders is provided. A method for expanding hematopoietic stem cells and/or hematopoietic progenitor cells, which comprises culturing hematopoietic stem cells and/or hematopoietic progenitor cells ex vivo in the presence of a compound represented by the formula (I) (wherein X, Y, X, Ar, R, R, R, R, R, Rand Rare defined in the description), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof. 

Method for expanding hematopoietic stem cells using heterocyclic compound

An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy useful for treatment of various disorders is provided. An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells is provided, containing a compound represented by the formula (I): 

Heterocyclic compounds and expansion agents for hematopoietic stem cells

An object of the present invention is to expand CD34cells ex vivo efficiently in a short term using a biologically safe and inexpensively obtainable low molecular weight compound. A still another object of the present invention is to provide an expansion agent for CD34cells useful for treatment of various hematopoietic disorders caused by dysfunctional hematopoietic stem cells and/or hematopoietic progenitor cells. A method for expanding CD34cells, which comprises culturing CD34cells ex vivo in the presence of a compound represented by the formula (I) (wherein A, B, L, L, L, L, R, R, R, X and Y are defined in the description), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof. 

Novel therapeutic agents for myeloma are provided. A therapeutic agent for multiple myeloma containing a pyrazole compound represented by the formula (1): 

Pyrazole compounds having therapeutic effect on multiple myeloma

To provide a novel process for producing a 2-aryl-3-hydroxy-4-substituted carbonyl thiophene compound or an intermediate thereof useful as an intermediate for production of medicines and agricultural chemicals. A 2-aryl acetate compound represented by the formula (1): wherein Ris an aryl group or the like, Ris a Calkyl group or the like, and X is a leaving group, is reacted with a thioacetic acid compound to form a thioacetyl compound (3), the thioacetyl compound (3) is reacted with a vinyl ketone compound to form a &#x3b3;-ketosulfide compound (5), which is cyclized under basic conditions to form a dihydrothiophene compound (6), and the dihydrothiophene compound (6) is oxidized by using an oxidizing agent to produce a 2-aryl-3-hydroxy-4-substituted carbonyl thiophene compound (7).

Process for producing thiophene compound and intermediate thereof

A compound represented by the formula (1): wherein A, B, R, L, R, L, L, Y, L, Rand X are the same as defined in the description, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof. 

3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators

Provided are &#x3b3;-ketosulfide compounds represented by the formula (5): where the structural variables R, R, Rand Rare as defined herein.

To provide a novel process for producing a 2-aryl-3-hydroxy-4-substituted carbonyl thiophene compound or an intermediate thereof useful as an intermediate for production of medicines and agricultural chemicals. A 2-aryl acetate compound represented by the formula (1): 

A compound represented by the formula (1): wherein A is a nitrogen atom or CR, B is an oxygen atom, a sulfur atom or NR(provided that when A is a nitrogen atom, B is not NH), Ris a Caryl group, Lis a bond, CRR, an oxygen atom, a sulfur atom or NR, X is OR, SRor NRNR, Ris a hydrogen atom, a formyl group, a Calkyl group or the like, Lis a bond or the like, Lis a bond, CRR, an oxygen atom, a sulfur atom or NR, Lis a bond, CRR, an oxygen atom, a sulfur atom or NR, Y is an oxygen atom, a sulfur atom or NR, and Ris a Caryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

Heterocyclic compounds and thrombopoietin receptor activators

Compounds effective for preventing, treatment or improving diseases against which activation of the thrombopoietin receptor is effective are provided. A compound represented by the formula (I) (wherein R, R, R, L, L, L, X and Y are defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof. 

Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators

A preventive, therapeutic or improving agent for diseases against which activation of the thrombopoietin receptor is effective or a platelet increasing agent, which contains a thrombopoietin receptor activator represented by the formula (1): wherein A is a C?2-14#191 aryl group, B is a hydrogen atom, a C?1-6#191 alkyl group, a C?1-3#191 alkyl group substituted with one or more fluorine atoms or a C?2-14#191 aryl group, D is a hydrogen atom, a C?1-6#191 alkyl group, a C?1-3#191 alkyl group substituted with one or more fluorine atoms or a C?2-14#191 aryl group, and E is a C?2-14#191 aryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the activator or a solvate thereof, as an active ingredient. 

Pyrazolone compounds and thrombopoietin receptor activator

Compounds effective for preventing, treatment or improving diseases against which activation of the thrombopoietin receptor is effective are provided. A compound represented by the formula (I) (wherein R, R, R, L, L, X and Y are defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof. 

Hydrazide compounds and thrombopoietin receptor activators

A compound represented by the formula (I) (wherein R, R, Rand Rare as defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof. 

Thiophene compounds and thrombopoietin receptor activators

Pyrazole compounds and thrombopoietin receptor activators

A preventive, therapeutic or improving agent for diseases against which activation of the thrombopoietin receptor is effective or a platelet increasing agent, which contains a thrombopoietin receptor activator represented by the formula (1): [wherein each of Rand Ris independently a hydrogen atom, SOH, a Calkyl group, a Calkylcarbonyl group or a Carylcarbonyl group (the Calkyl group, the Calkylcarbonyl group and the Carylcarbonyl group may be optionally substituted with a halogen atom, a hydroxyl group, a Calkenyl group, a Calkoxy group, a Calkoxycarbonyl group, a Caryl group, a 2-pyridyl group, a 3-pyridyl group, a 4-pyridyl group, a 2-furanyl group, a 3-furanyl group, a 2-thienyl group, a 3-thienyl group or NRR) , and each of R, Rand Ris independently a hydrogen atom, a hydroxyl group or a Calkoxy group].

Growing community of inventors

Funabashi, Japan

Katsuaki Miyaji